FDA approves first interchangeable biosimilar product for Humira
The Food and Drug Administration today approved the first interchangeable biosimilar product for Humira, a monoclonal antibody used to treat certain inflammatory diseases. The product (Cyltezo) is approved to treat certain adult and pediatric patients with arthritis or Crohn’s disease, and certain adults with ulcerative colitis or psoriasis.
Related News Articles
Headline
The AHA Aug. 12 provided comments to the Consumer Product Safety Commission on its agenda and priorities for fiscal years 2027 and 2028, specifically…
Headline
The Food and Drug Administration Aug. 3 identified Class I recalls of two convenience kit products. Certain kits by Medline…
Headline
The Food and Drug Administration has identified a recall by Cook Medical of Zenith Alpha 2 Thoracic Endovascular Graft proximal components after Cook Medical…
Headline
The Food and Drug Administration has issued early alerts for certain Spectrum infusion pumps from Baxter and Abiomed Automated Impella Controllers. The agency…
Headline
The White House Feb. 1 announced it placed tariffs on imported goods from Canada, Mexico and China. The tariffs for Mexico and Canada have since been delayed…
Headline
The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may…